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LETTERS TO THE EDITOR
BRIDGE Study Warrants Critique
T heBipolarDisorders: ImprovingDiagnosis, Guid-ance and Education (BRIDGE) study1 by Angstet al has received coverage in psychiatric online
media.2-4 Themessage is that almost half the patients with
amajor depressive episode have undiagnosed bipolar dis-
order and are “not receiving necessary mood stabilizer
treatment.”2 Such views are controversial and far from
themainstreamas reflected in International Statistical Clas-
sification of Diseases, 10th Revision and DSM-IV. Yet the
BRIDGE study findings were published without accom-
panying commentary or critique.
The study’s findings are based on a “bipolar speci-
fier” requiring “nominimumduration of symptoms” and
“no exclusion criteria.” Any subject who came to psy-
chiatric attention with an angry, agitated, or elated re-
sponse to environmental triggers or psychoactive sub-
stances might havemet criteria for “bipolarity.” The lack
of duration requirements means any subject with epi-
sodic affective instability (eg, borderline personality dis-
order or posttraumatic symptoms) is liable to be misla-
beled as having bipolar disorder. Notmentionedwas that
the self-report “bipolar-specifier” instrument was previ-
ously reported to have a specificity of only 51%.5
The study based “subthresholdmania” on just 3 symp-
toms (eg, “beingmore talkative, [having] decreased need
for sleep, and increased goal-directed activity”). In the
absence of coremanic symptoms, many clinicians would
inquire about anxiety and considermanic defenses to con-
textual stressors. The article does not define how behav-
ior was determined to be an “unequivocal and observ-
able change in functioning uncharacteristic of the person’s
usual behavior.”1(p793) Patients with borderline person-
ality disorder or substance abuse frequently report these
sorts of behavioral changes.
Further, 23.2% of subjects were reported to experi-
ence elevated or irritable mood triggered by antidepres-
sants and were defined as having bipolar disorder. Irri-
tability is a common adverse effect of selective serotonin
reuptake inhibitors. Angst et al presumed that anyone
with this adverse effect actually had bipolar disorder. This
conflicts with the literature6 and with a 6-decade retro-
spective study by Angst of swings from depression toma-
nia concluding “there is no evidence for a treatment-
induced (manic) switch.”7(p140) Yet Angst et al do not
comment on this apparent change in perspective.
The article reports “the sponsor of this study (sanofi-
aventis) was involved in the study design, conduct,moni-
toring, data analysis, and preparation of the re-
port.”1(p798) Participating psychiatrists were financially
remunerated for patient recruitment. The article con-
cluded with an appeal to use “mood stabilizers,” pre-
sumably atypical antipsychotics, which are less effica-
cious than lithium.8 The sponsor has amedication in this
class. Other pharmaceutical company documents indi-
cate a desire for a widening of bipolar diagnostic crite-
ria.9 Angst et al advocate treatment with such drugs for
“symptoms that impair everyday functioning,”1(p797) but
according to Table 2 in their article,1(p795) more than 40%
of patients whomet subthreshold bipolar criteria had no
lifetime history of such impairment.
Angst et al state that a study limitation was that “par-
ticipating centers were not randomly selected, whichmay
have led to a bias through inclusion of psychiatrists with
a particular interest in bipolar disorder.”1(p797) This is not
a trivial point. Opposing perspectives in psychiatry that
consider or do not consider the influence of reactive dy-
namic forces on contextual factors have been labeled at
the extreme as “brainless psychiatry” and “mindless psy-
chiatry.”10 The ever-widening “bipolar spectrum” is the
current focus for this debate.11-13 The BRIDGE study find-
ings would have been better presented with a critique
couched within this debate.
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In reply
We are pleased to respond to the points raised by Allen et
al, some of which takematerial out of context and quote news
media articles beyond our control. For example, the letter
states that “Themessage is that almost half the patients with
a major depressive episode have undiagnosed bipolar dis-
order and are ‘not receiving necessarymood stabilizer treat-
ment.’” Our actual statements are:
Based on these studies and the major differences in treatment
guidelines forMDD [major depressive disorder] and bipolar dis-
order, we recommend that, among patients with MDEs [major
depressive episodes], the presence of bipolar features, includ-
ingall thosewith significantpredictive value reported in this study,
should be investigated carefully before a decision ismade to pre-
scribe antidepressants. If patients exhibit bipolar symptoms that
impair everyday functioning, treatment with a mood stabilizer
or an atypical antipsychotic may be useful.1(p797)
They assert that “The study’s findings are based on a
‘bipolar specifier’ requiring ‘no minimum duration of
symptoms’ and ‘no exclusion criteria,’ ” and that “Any
subject who came to psychiatric attention with an angry,
agitated, or elated response to environmental triggers or
psychoactive substances might have met criteria for ‘bipo-
larity.’ ” The criteria, stated in the “Methods” section of
our article,1(p793) were (1) an episode of elevated mood, an
episode of irritable mood, or an episode of increased
activity with (2) at least 3 of the symptoms listed under
Criterion B of the DSM-IV-TR associated with (3) at
least 1 of the 3 following consequences: unequivocal and
observable change in functioning uncharacteristic of the
person’s usual behavior, marked impairment in social or
occupational functioning observable by others, or requir-
ing hospitalization or outpatient treatment. The mini-
mum duration of symptoms required for a hypomanic
episode was 1 day. We assessed the duration reported for
hypomanic episodes in 5 groups. Among subjects with
major depressive episode with hypomanic episodes, 7.8%
reported episodes of 1 day’s duration; 2 to 3 days’ dura-
tion was more frequent than 4 to 6 days.2 No exclusion
criteria for manic/hypomanic episodes associated with
antidepressant or other drug use were applied. Impor-
tantly, the initial eligibility criterion was that patients
have presented to clinical settings for evaluation and
treatment of a major depressive episode per DSM-IV-TR
criteria. These sequential criteria, applied by senior psy-
chiatrists in each country, are entirely inconsistent with
the assertion that the psychiatrists conducting the assess-
ments enrolled “any subject who came to psychiatric
attention with an angry, agitated, or elated response to
environmental triggers.”
The statement that 23.2% of subjects experienced el-
evated or irritable mood triggered by antidepressants did
not “define the subjects as having ‘bipolar disorder.’” Rather,
it addresses theDSMA criteria, which are essential, but not
sufficient, for diagnosis of bipolar disorder. As Figure 1 in
our article1(p794) shows, mood lability while taking antide-
pressants occurred in 55.8% of bipolar specifier–positive vs
23.0% of bipolar specifier–negative subjects (odds ratio, 1.7;
95% CI, 1.4-2.0) and mania/hypomania while taking anti-
depressants occurred in 37.2% of bipolar specifier–positive
vs 3.4% of bipolar specifier–negative subjects (odds ratio,
5.7; 95% CI, 4.4-7.5).
Allen et al view their position as part of a “debate” about
the “ever-widening bipolar spectrum.”We consider data, not
debates, as central to the progress in the scientific under-
standing of mood disorders. They make several references
to borderline personality disorder. The BRIDGE study as-
sessed for comorbid diagnoses in all subjects. Five hundred
thirty-two patients (9.3%)metDSM-IV-TR criteria for bor-
derline personality disorder. This large sample provides an
opportunity to analyze patients who met borderline crite-
ria vs those who did not. We are completing a manuscript
that will provide useful evidence on this subject.
Allen et al cast unseemly aspersions that the BRIDGE
study was a vehicle to promote sales of an antipsychotic
drug sold by sanofi-aventis. sanofi-aventis has no anti-
psychotic with an indication for bipolar disorder. We
know of no evidence that this was the case at any stage of
development and execution of the BRIDGE study. sanofi-
aventis ceased financial support for analyses of the study
in 2010. All work subsequently conducted has been
achieved by our local funds.
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